Boston's optimism on Guidant buy unwavering
This article was originally published in Clinica
Executive Summary
Boston Scientific has reinforced its bullish outlook on the pending $27bn acquisition of Guidant, dismissing fears that the company could be stretching its finances too thin with the hefty transaction.